Login to Your Account



DRUG GRADUATES TO I-SPY PHASE III

Neratinib beats Herceptin in breast cancer trial; Puma’s stock soars

By Catherine Shaffer
Staff Writer

Friday, December 6, 2013
Positive results in a Phase II trial of its breast cancer drug neratinib sent stock in Puma Biotechnology Inc. skyrocketing 68 percent Thursday. In the trial, a combination of neratinib and Taxol unexpectedly outperformed a Herceptin/Taxol combination by 18 percent to 19 percent, according to analyst estimates.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription